UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

87 Mesothelin-targeted immunotherapy CRS-207 plus chemotherapy as treatment for malignant pleural mesothelioma (MPM)

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S31-S32

2016

Volltextzugriff (PDF)

Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium

The Journal of clinical investigation, 1988-10, Vol.82 (4), p.1454-1461

1988

Volltextzugriff (PDF)

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

The New England journal of medicine, 1991-07, Vol.325 (3), p.164-170

1991

Volltextzugriff (PDF)

GCS-100, a galectin-3 antagonist, in refractory solid tumors: A phase I study

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13023-13023

2006

Volltextzugriff (PDF)

Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.9627-9627

2009

Volltextzugriff (PDF)

CRS-207 vaccine plus chemotherapy as front-line treatment for subjects with malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS7607-TPS7607

2013

Volltextzugriff (PDF)

Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7565-7565

2015

Volltextzugriff (PDF)

Adenocarcinoma of the Urachus Associated with Elevated Levels of CA 125

The Journal of urology, 1991-01, Vol.145 (1), p.140-141

1991

Volltextzugriff (PDF)

Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7060-7060

2004

Volltextzugriff (PDF)

Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7060-7060

2004

Volltextzugriff (PDF)

A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4159-TPS4159

2014

Volltextzugriff (PDF)

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7532-7532

2014

Volltextzugriff (PDF)

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

The New England journal of medicine, 1988-06, Vol.318 (22), p.1414-1422

1988

Volltextzugriff (PDF)

A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.TPS489-TPS489

2015

Volltextzugriff (PDF)

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.177-177

2014

Volltextzugriff (PDF)

Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4040-4040

2013

Volltextzugriff (PDF)

Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas

Journal of neurosurgery, 1997-04, Vol.86 (4), p.603-609

1997

Volltextzugriff (PDF)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P161-P161, Article P161

2015

Volltextzugriff (PDF)

Compassionate-Use Gefitinib in Non–Small Cell Lung Cancer: Survival and Safety in 21,064 Patients in an Expanded Access Program

Chest, 2004-10, Vol.126 (4), p.731S-731S

2004

Volltextzugriff (PDF)

Prospective Assessment of Neuropsychological Function and Quality of Life (QOL) in a Clinical Trial for Malignant Brain Tumors

Quality of life research, 1995-10, Vol.4 (5), p.463-463

1995

Volltextzugriff (PDF)

Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7013-7013

2004

Volltextzugriff (PDF)

Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7013-7013

2004

Volltextzugriff (PDF)

Feature

American Bankruptcy Institute journal, 2011-09, Vol.30 (7), p.20

2011

Volltextzugriff (PDF)

825 Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (‘Iressa’, ZD1839) in an expanded access program (EAP): preliminary results

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S248-S248

2003

Volltextzugriff (PDF)

A phase I trial of RSR13, a novel radioehancing agent, in adults with newly diagnosed glioblastoma

International journal of radiation oncology, biology, physics, 1998, Vol.42 (1), p.198-198

1998

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

87 Mesothelin-targeted immunotherapy CRS-207 plus chemotherapy as treatment for malignant pleural mesothelioma (MPM)

Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

GCS-100, a galectin-3 antagonist, in refractory solid tumors: A phase I study

Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)

CRS-207 vaccine plus chemotherapy as front-line treatment for subjects with malignant pleural mesothelioma (MPM)

Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM)

Adenocarcinoma of the Urachus Associated with Elevated Levels of CA 125

Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)

Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP)

A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results

Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer

Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

Compassionate-Use Gefitinib in Non–Small Cell Lung Cancer: Survival and Safety in 21,064 Patients in an Expanded Access Program

Prospective Assessment of Neuropsychological Function and Quality of Life (QOL) in a Clinical Trial for Malignant Brain Tumors

Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy

Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy

Feature

825 Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (‘Iressa’, ZD1839) in an expanded access program (EAP): preliminary results

A phase I trial of RSR13, a novel radioehancing agent, in adults with newly diagnosed glioblastoma

Suchergebnisse filtern